ENTA
Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc.ENTA

Healthcare · Biotechnology
10.65USD
+2.70%
Nov 05, 2026
ENTA overview ready
Developer of small molecule antiviral and immunology drugs for healthcare markets
Enanta Pharmaceuticals discovers and develops small molecule drugs targeting virology and immunology diseases, advancing candidates through clinical trials toward commercialization.
Theme not measured
No economic group is assigned yet.
Price trend is broken
Longer-term context reads damaged structure, with a near-term setup of distribution pressure.
The tactical setup reads distribution pressure, but the weekly structure is broken.
Demanding valuation
The price embeds expectations that run ahead of the cash it currently generates.
Fundamentals not measured
Market Nov 4Filing Jun 30Price action Nov 5

Conviction Level

Theme Momentum has no canonical measurement for this company — a research-profile dimension, not an input to this score.

PriceAction3.4BusinessPerformance2.0BusinessQuality—Valuation3.2ThemeMomentum—Weakening — Revenue fell 22% year over year in the latest quarter. The company is still loss-making: the diluted loss per share narrowed to -$0.67 from -$0.85 a year earlier. — From filed financial statements. Describes the recent trajectory of the business, not the stock. 20 of the 100 Conviction points.

Conviction uses Price Action, Business Performance, Business Quality, Valuation. Theme Momentum is research context, not an input.

Theme momentumPrimary theme · group context, not entry timing
No economic group yet — pending research
Price
Loading price history…

Price Action

Price trend is broken
Longer-term context reads damaged structure, with a near-term setup of distribution pressure.
The tactical setup reads distribution pressure, but the weekly structure is broken.
EntryWeak / unconfirmed recovery

The daily chart may be improving, but the weekly fast averages have not been reclaimed — the recovery is not yet confirmed on the higher timeframe.

Key Financials

Market Cap
$310.2M
Avg Volume (60D)
264.4K
60 sessions
Revenue Growth YoY
-3.4%
FY2025 vs FY2024
Gross Margin
+100.0%
Operating Margin
-90.0%
Trailing twelve months
Free Cash Flow Yield
-11.9%
P/E
N/M
Market metrics as of Nov 4, 2026
Financial results for the period ended Jun 30, 2026
Filed balance-sheet data as of Jun 30, 2026

Business Performance

Weakening

Revenue fell 22% year over year in the latest quarter. The company is still loss-making: the diluted loss per share narrowed to -$0.67 from -$0.85 a year earlier.

Latest reported: Q3 FY2026, ended Jun 30
Revenue growthDeclining
-22%
$14.4M in Q3 FY2026 · YoY
YoY growth, last 4 quarters
  1. +3.5%
  2. +9.8%
  3. +15%
  4. -22%
Earnings growthLoss narrowing
-$0.67
Diluted EPS -$0.67 vs -$0.85 a year earlier · GAAP
Too few comparable EPS quarters: a loss or a turn to profit has no meaningful percentage.
Operating marginSwinging
-120.0%
-16.9 pp YoY
The business is consuming cash
The share count is rising

Business Quality

Not assessed

Not assessed yet — the business is too early-stage for its economics to show in filings.

Fundamentals & Valuation

The available comparisons disagreed; the intrinsic comparison is the more reliable method for this business and the others are published as dissent.
Enanta Pharmaceuticals, Inc. has an Expensive valuation stance because the price embeds expectations that run ahead of the cash it currently generates.

Company Research

Research coverage for this company is in progress.

Economic classification

Loading the economic classification…

Business & Markets

Healthcare · Biotechnology
What they do

Enanta Pharmaceuticals discovers and develops small molecule drugs targeting virology and immunology diseases, advancing candidates through clinical trials toward commercialization.

How it earns

Revenue is generated primarily through product sales and licensing agreements related to its drug candidates.

Products & services
EDP-514 (HBV treatment)
Zelicapavir (RSV treatment)
EDP-323 (RSV treatment)
EDP-235 (human coronavirus treatment)
EDP-978 (chronic spontaneous urticaria)
Glecaprevir (antiviral protease inhibitor)
Customers & end markets
Pharmaceutical companies
Healthcare providers
Patients with viral and immunological diseases
Market position

Niche biotechnology company focused on small molecule antivirals and immunology therapies.

Demand drivers
Low cyclicality

Demand for pharmaceutical innovation and treatments in virology and immunology is relatively stable and driven by medical need rather than economic cycles.